Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Last updated: April 29, 2025
Sponsor: Gateway Institute for Brain Research
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

INS-GSH

Matched Placebos

Clinical Study ID

NCT05266417
20-GTY-008-01
  • Ages 30-85
  • All Genders

Study Summary

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

Eligibility Criteria

Inclusion

Key Inclusion Criteria:

  • Documented clinical diagnosis of idiopathic PD

  • Modified HY stage < 5

  • Able to administer study drug or have a caregiver throughout the duration of thestudy to help administer drug

  • Willing to continue diet, exercise and medications reported at baseline consistentlythroughout participation in the trial. Essential changes are permitted

  • If taking PD medications or any nutraceuticals, must be on a stable dose for atleast 30 days prior to Screening Visit. Essential changes will be permitted.

  • If subject is taking chronic antidepressant or an anxiolytic, must be on a stabledose for at least 90 days prior to Screening. Essential changes will be permitted.

Exclusion

Key Exclusion Criteria:

  • Clinical diagnosis of Type 1 or Type 2 Diabetes Mellitus

  • Glycated hemoglobin (HbA1c) level ≥ 6.5%

  • History of hypoglycemia and/or documented plasma glucose levels of ≤ 50 mg/dL withor without symptoms of hypoglycemia

  • Mini-Mental State Exam (MMSE) score of ≤ 24 at Screening

  • Positive COVID-19 test at Screening and/or within 30 days of Screening

  • Change in or escalation of dose of a chronic therapeutic agent that has thepotential to impair cognitive functioning

  • Chronic inflammation of nasal cavity that may prevent absorption of study treatments

  • Insufficiently controlled respiratory disease (i.e., asthma, COPD).

  • History of any significant neurologic or psychiatric disease other than PD

  • Current diagnosis of epilepsy and had a history of seizures as an adult within 1year of Screening, or unexplained recent loss of consciousness, or history ofsignificant head trauma with loss of consciousness

  • History of non-lacunar ischemic and/or hemorrhagic stroke

  • Unstable or uncontrolled cardiac disease that could expose the subject to additionalsafety risks

  • Use of the following medications: Insulin or any other anti-hyperglycemic agent(s)except if used during isolated gestational diabetes, Supplementation with GSH or anymedication shown to increase glutathione, and Beta Blockers

Study Design

Total Participants: 56
Treatment Group(s): 2
Primary Treatment: INS-GSH
Phase: 2
Study Start date:
February 07, 2022
Estimated Completion Date:
January 30, 2027

Connect with a study center

  • Institute for Neuroimmune Medicine

    Davie, Florida 33314
    United States

    Active - Recruiting

  • Las Mercedes Medical Research

    Hialeah, Florida 33012
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.